Repare Therapeutics Inc.
NASDAQ Global SelectTotal Valuation
Repare Therapeutics Inc. carries a market capitalization of 114.24M, placing it among publicly traded companies globally. Its enterprise value stands at -36.89M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 114.24M |
| Enterprise Value | -36.89M |
Share Statistics
Repare Therapeutics Inc. currently has 42.99M shares outstanding.
| Shares Outstanding | 42.99M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 6.35, and the price-to-book ratio stands at 2.58.
| PE Ratio | N/A |
| PS Ratio | 6.35 |
| PB Ratio | 2.58 |
| P/TBV Ratio | 0.65 |
| P/FCF Ratio | -1.08 |
| P/OCF Ratio | -1.07 |
Financial Position
Repare Therapeutics Inc. maintains a current ratio of 10.71, meaning it holds 10.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 10.71 |
| Quick Ratio | 10.40 |
| Debt / Equity | 0.30 |
| Debt / EBITDA | 0.00 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -113.96 |
| Return on Assets (ROA) | -43.35 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Taxes
Over the trailing twelve months, Repare Therapeutics Inc. has paid 763,000.00 in income taxes, reflecting an effective tax rate of 4.26.
| Income Tax | 763,000.00 |
| Effective Tax Rate | 4.26 |
Stock Price Statistics
Repare Therapeutics Inc.'s stock has gained approximately 120.83333% over the past 52 weeks. The 50-day moving average sits at 2.35, while the 200-day moving average is 1.75.
| Beta (5Y) | N/A |
| 52-Week Price Change | 120.83333% |
| 50-Day Moving Average | 2.35 |
| 200-Day Moving Average | 1.75 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Repare Therapeutics Inc. generated 11.87M in revenue and converted that into -72.20M in net income, yielding earnings per share of -1.68. EBITDA reached -76.46M, while operating income came in at -79.21M.
| Revenue | 11.87M |
| Gross Profit | N/A |
| Operating Income | -79.21M |
| Pretax Income | -71.44M |
| Net Income | -72.20M |
| EBITDA | -76.46M |
| EBIT | -79.21M |
| Earnings Per Share (EPS) | -1.68 |
Balance Sheet
Repare Therapeutics Inc. holds 112.60M in cash and equivalents against 342,000.00 in total debt, resulting in a net debt position of -72.82M. Total book value stands at 29.16M, with working capital of 112.81M providing operational flexibility.
| Cash & Cash Equivalents | 112.60M |
| Total Debt | 342,000.00 |
| Net Debt | -72.82M |
| Equity (Book Value) | 29.16M |
| Book Value Per Share | 0.68 |
| Working Capital | 112.81M |
Cash Flow
Repare Therapeutics Inc. produced -70.15M in operating cash flow over the past twelve months.
| Operating Cash Flow | -70.15M |
| Capital Expenditures | N/A |
| Free Cash Flow | -70.15M |
| FCF Per Share | -1.64 |
Margins
Repare Therapeutics Inc. operates with a gross margin of 100.00, reflecting its pricing power and cost economics. The operating margin of -667.31 and net profit margin of -608.26 provide insight into operational efficiency.
| Gross Margin | 100.00 |
| Operating Margin | -667.31 |
| Pretax Margin | -601.83 |
| Profit Margin | -608.26 |
| EBITDA Margin | -644.16 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -0.15 |
| FCF Yield | -93.00 |
Scores
Repare Therapeutics Inc. posts an Altman Z-Score of -2.10, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -2.10 |